Hopstem Biotechnology is among the Top 50 Most Innovative Chinese Biomedical Companies in 2019
The Xingyao award ceremony, also known as the first Global Bio-pharmaceutical CDMO Development Summit Forum with the theme of Innovation and Inheritance, was held at Four Points by Sheraton Hotel on August 3rd and 4th 2019.
The Xingyao Institute of MedClub united dozens of companies and professional investment institutions to launch the selection campaign of "the Top 50 Most Innovative Chinese Biomedical Companies in 2019". The goal of this campaign was to conduct comprehensive observations and evaluations on the innovation activities and innovation abilities of biopharmaceutical companies in China. This campaign will serve as an important reference and is valuable for evaluating the innovation ability of the domestic innovative drug research companies, which are the bellwethers of the industry.
All participants in the campaign are from the first-line innovative biomedical companies in the field, and most of them are public traded domestic pharmaceutical companies. After repeated scrutiny by experts and institutions in related fields, Hopstem Biotechnology stood out from more than 300 pharmaceutical companies and was awarded "the Top 50 Most Innovative Chinese Biomedical Companies in 2019" because of its international leading stem cell neural differentiation technology, continuous research, and innovation ability. Hopstem Biotechnology is grateful to the experts from the biomedical field and related institutions for their recognition of Hopstem’s research and current status in the field. Hopstem will continue working hard to promote the research and development of new cell therapy products and contribute to society.
Combine the power of Neuroscience and Stem Cells to understand and treat neural disorders better